UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 146

Sortiert nach

Altered brain concentrations of citalopram and escitalopram in P-glycoprotein deficient mice after acute and chronic treatment

European neuropsychopharmacology, 2013-11, Vol.23 (11), p.1636-1644

2013

Volltextzugriff (PDF)

Blood–brain barrier penetration of the enantiomers of venlafaxine and its metabolites in mice lacking P-glycoprotein

European neuropsychopharmacology, 2010-09, Vol.20 (9), p.632-640

2010

Volltextzugriff (PDF)

Response, remission and relapse in relation to adherence in primary care treatment of depression: a 2-year outcome study

International clinical psychopharmacology, 2006-03, Vol.21 (2), p.117

2006

Volltextzugriff (PDF)

Reboxetine modulates the firing pattern of dopamine cells in the ventral tegmental area and selectively increases dopamine availability in the prefrontal cortex

The Journal of pharmacology and experimental therapeutics, 2001-05, Vol.297 (2), p.540

2001

Volltextzugriff (PDF)

Therapeutic drug monitoring data on Olanzapine and its N-demethyl metabolite in the naturalistic clinical setting

Therapeutic drug monitoring, 2002-08, Vol.24 (4), p.518-526

2002

Volltextzugriff (PDF)

Therapeutic drug monitoring of racemic citalopram: A 5-year experience in Sweden, 1992-1997

Therapeutic drug monitoring, 2003-04, Vol.25 (2), p.183-191

2003

Volltextzugriff (PDF)

Calcium fluxes, calcium antagonists, and calcium-related pathology in brain ischemia, hypoglycemia, and spreading depression: a unifying hypothesis

Journal of cerebral blood flow and metabolism, 1989-04, Vol.9 (2), p.127

1989

Volltextzugriff (PDF)

Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting

Therapeutic drug monitoring, 2002-08, Vol.24 (4), p.545-553

2002

Volltextzugriff (PDF)

Identification of primary care patients at risk of nonadherence to antidepressant treatment

Patient preference and adherence, 2008-02, Vol.2 (default), p.379-386

2008

Volltextzugriff (PDF)

Therapeutic drug monitoring of psychotropic drugs. TDM "nouveau"

Therapeutic drug monitoring, 2004-04, Vol.26 (2), p.145

Bengtsson, Finn

2004

Volltextzugriff (PDF)

Stereoselective single-dose kinetics of citalopram and its metabolites in rats

Chirality (New York, N.Y.), 2003, Vol.15 (7), p.622-629

2003

Volltextzugriff (PDF)

Serum levels of citalopram and its main metabolites in adolescent patients treated in a naturalistic clinical setting

Journal of clinical psychopharmacology, 2002-08, Vol.22 (4), p.406-413

2002

Volltextzugriff (PDF)

Short Onset of Action of a Serotonin Reuptake Inhibitor When Used to Reduce Premenstrual Irritability

Neuropsychopharmacology (New York, N.Y.), 2009-02, Vol.34 (3), p.585-592

2009

Volltextzugriff (PDF)

Effects on enantiomeric drug disposition and open-field behavior after chronic treatment with venlafaxine in the P-glycoprotein knockout mice model

Psychopharmacologia, 2011-05, Vol.215 (2), p.367-377

2011

Volltextzugriff (PDF)

Influence of CYP2D6 genotype on the disposition of the enantiomers of venlafaxine and its major metabolites in postmortem femoral blood

Forensic science international, 2012-01, Vol.214 (1), p.124-134

2012

Volltextzugriff (PDF)

Cyclosporin A, But Not FK 506, Protects Mitochondria and Neurons against Hypoglycemic Damage and Implicates the Mitochondrial Permeability Transition in Cell Death

The Journal of neuroscience, 1998-07, Vol.18 (14), p.5151-5159

1998

Volltextzugriff (PDF)

ABCB1 gene polymorphisms are associated with fatal intoxications involving venlafaxine but not citalopram

International journal of legal medicine, 2013-05, Vol.127 (3), p.579-586

2013

Volltextzugriff (PDF)